CA
NZ
UK
AU
IND
US
● ADVB shares rocketed 14.46% without a confirmed corporate catalyst, fitting the stock's established pattern of sharp, momentum-driven bursts.
● BLSM shares jumped 14.91% without a defining company announcement, reflecting a broader lift in risk appetite across biotech.
● GENB shares climbed 15.01% amid a broad re-rating of AI-enabled and computational drug-discovery names, without a single company-specific catalyst.
● MRNA shares rose 14% as investors continued to reward the Phase 3 success of Moderna and Merck's individualized cancerVaccinein melanoma.
● TENX shares jumped 25.41% in a rebound that recovers only a fraction of the value erased when the stock plunged roughly 90% on August 10 after its Phase 3 LEVEL trial missed its primary endpoint.
● AMIX shares broke out roughly 34% after an investor exercised 857,462 warrants at $5.75 per share, generating roughly $4.9 million in gross proceeds.
● CAPR shares surged 21.91% after the FDA agreed to consider an amendedBiologicslicense application for deramiocel centered on upper-limb skeletal muscle function in Duchenne muscular dystrophy.
● Second-quarter 2026Revenuefell about 76% to roughly $4.05 million from $17.08 million a year earlier, while the net loss widened to about $55.4 million from $34.7 million.
● AVXL shares surged 14.47% after a fiscal third-quarter update reframed the regulatory path for lead candidate blarcamesine and reassured investors about the company's financial staying power.
● EIKN shares rose 12.46% as investors positioned ahead of the ESMO Congress in late October, where seven abstracts covering the company's pipeline have been accepted.
Please wait processing your request...